Fate Therapeutics Files 8-K on Financials and Operations
Ticker: FATE · Form: 8-K · Filed: Aug 12, 2025 · CIK: 1434316
| Field | Detail |
|---|---|
| Company | Fate Therapeutics Inc (FATE) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $0.9 million, $1.2 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, disposal-activities
TL;DR
Fate Therapeutics dropped an 8-K on Aug 7th covering financials and operations - check it for the latest.
AI Summary
On August 7, 2025, Fate Therapeutics, Inc. filed an 8-K report detailing results of operations and financial condition. The filing also covers costs associated with exit or disposal activities and includes financial statements and exhibits. The company is based in San Diego, California.
Why It Matters
This 8-K filing provides crucial updates on Fate Therapeutics' financial health and operational status, which are important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful investor review.
Key Players & Entities
- Fate Therapeutics, Inc. (company) — Registrant
- August 7, 2025 (date) — Date of earliest event reported
- San Diego, CA (location) — Principal executive office location
- 858 875-1800 (phone_number) — Registrant's Telephone Number
FAQ
What specific financial information is being disclosed in this 8-K filing?
The 8-K filing indicates disclosure of 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
Does this filing mention any restructuring or disposal activities?
Yes, the filing explicitly lists 'Cost Associated with Exit or Disposal Activities' as an item being reported.
What is the principal executive office address for Fate Therapeutics, Inc.?
The principal executive office is located at 12278 Scripps Summit Dr., San Diego, CA 92131.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated August 7, 2025.
What is the SIC code for Fate Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Fate Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 830 words · 3 min read · ~3 pages · Grade level 11.8 · Accepted 2025-08-12 16:07:27
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value FATE Nasdaq Global Market
- $0.9 million — it will incur charges of approximately $0.9 million to $1.2 million for severance and other
- $1.2 million — harges of approximately $0.9 million to $1.2 million for severance and other employee termin
Filing Documents
- d452012d8k.htm (8-K) — 28KB
- d452012dex991.htm (EX-99.1) — 84KB
- 0001193125-25-178947.txt ( ) — 234KB
- fate-20250807.xsd (EX-101.SCH) — 3KB
- fate-20250807_lab.xml (EX-101.LAB) — 17KB
- fate-20250807_pre.xml (EX-101.PRE) — 11KB
- d452012d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by such words as "expect," "anticipate," "intend," "estimate," and words of similar import and are based on current expectations that involve risks and uncertainties, such as the Company's plans, objectives, expectations and intentions. All statements other than historical or current facts are forward-looking statements, including, without limitation, statements about the expected timing, magnitude and financial impact of the Restructuring and the RIF, anticipated extension of the Company's cash runway, and the terms and conditions associated with the termination of employees. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially and adversely from those anticipated in the forward-looking statements. The statements in this Current Report on Form 8-K, including all forward-looking statements, speak only as of the date of this report. Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description 99.1 Press Release dated August 12, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 12, 2025 FATE THERAPEUTICS, INC. By: /s/ Bahram Valamehr Bahram Valamehr, Ph.D., M.B.A. President and Chief Executive Officer